However, since ERCC1 is also involved in the repair of cisplatin-induced DNA adducts in cancer cells, high expression levels increase resistance to platinum-based chemotherapies [75], [76], while low expression leads to drug sensitivity [77]. Here, ERCC1 is linked to cancer.